


Dapagliflozin: Secondary benefit of weight loss compared with a sulphonylurea



*Dapagliflozin dose was up-titrated to a maximum of 10mg (achieved in 87% of patients) over an 18-week period based on glycaemic response and tolerability

Data are adjusted mean change from baseline and 95% CI derived from a repeated measures mixed model. This was an exploratory endpoint from a long-term follow-up study. Weight loss in the initial 52 week study was a key secondary endpoint and was measured using LOCF analysis. Results at 52 weeks were -3.22 kg in the dapagliflozin arm (baseline weight 88.4 kg) and +1.44 kg in the SU arm (baseline weight 87.6 kg).

1, Nauck MA *et al*. *Diabetes Care* 2011;**34**:2015–2022.

2. Nauck M *et al*. Presented at: American Diabetes Association (ADA); June 24-28, 2011; San Diego, CA.